View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
December 21, 2021updated 07 Jan 2022 6:12am

Molnupiravir Q4 forecast sales grow by 17,500% compared to Q3 forecast

Merck’s molnupiravir oral antiviral for Covid-19 is expected to generate $14.7bn in sales over the next four years.

By GlobalData Healthcare

Fourth-quarter (Q4) 2021 forecast sales of Merck & Co’s Covid-19 oral antiviral, molnupiravir, have seen a phenomenal increase from its third-quarter (Q3) forecasts, with increases of 17,500% and 7,986% for this year and next year respectively. Molnupiravir is currently the leading Covid-19 therapeutic by forecast sales and is expected to generate $14.7bn in sales from 2021 to 2025 driven by high forecast sales from 2021–22, according to GlobalData’s Coronavirus Disease 2019 (Covid-19) Sector Forecast: Q4 2021 Global Analyst Consensus Sales report.

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

Molnupiravir is currently the first approved oral antiviral Covid-19 therapeutic on the market, approved by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on 4 November by emergency use authorisation (EUA). Developed by Merck and Ridgeback Biotherapeutics, the drug is a ribonucleoside analogue that acts as an antiviral agent. It is formulated as hard capsules for oral administration and is indicated for the treatment of mild to moderate Covid-19 in adults who have at least one risk factor for developing severe illness.

According to the Coronavirus Disease 2019 (Covid-19) Sector Forecast: Q4 2021 Global Analyst Consensus Sales report, the Q4 2021 forecast for molnupiravir saw the forecast sales for 2021 and 2022 increase by $4.4bn and $8.1bn respectively. Overall, molnupiravir’s Q4 2021 forecast has seen an average increase of 3,747% compared to its previous Q3 2021 forecast in September and saw large increases in forecast sales in five out of the seven forecast years, as indicated in Figure 1. This increase has led to molnupiravir’s forecast sales between last year and 2027 increasing exponentially from forecast sales of $1.4bn in the Q3 forecast to $14.7bn in the Q4 forecast.

This huge increase in forecast sales has been precipitated by the EUA awarded to molnupiravir by the UK’s MHRA, making it the first oral antiviral therapeutic approved for Covid-19. This is coupled with its oral route of administration, which has been hailed as a game-changer for possible at-home administration, which may lessen pressure on hospitals and healthcare providers as current Covid-19 therapeutics such as Veklury and REGN-COV2 require professional administration. This is of particular importance considering the increase in Covid-19 infections during this winter period, as well as the increase in breakthrough infections among vaccinated people.

Despite this surge in its forecast sales, there are concerns that the data available at the time of the forecast may be optimistic, considering that more recent analysis was published showing that molnupiravir’s ability to reduce the risk of hospitalisation or death by half—as originally thought—is in fact 20% less, providing only a 30% reduction. Pfizer’s oral antiviral Paxlovid has currently been shown to reduce the risk of hospitalisation by 89%; despite being first to market, molnupiravir may struggle to match these impressive sales forecasts in the face of competition.

Related Companies

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology